S.BIOMEDICS Cell Therapy for Parkinson’s Disease Shows Positive Data from Its Phase 1/2a Clinical Trial
Seoul, South Korea – 21/07/2025 – (SeaPRwire) – S.BIOMEDICS announced encouraging one-year post-transplant results from Phase 1/2a clinical trial evaluating A9-DPC cell therapy for Parkinson’s disease. The data demonstrate a favorable safety and efficacy profile of A9-DPC in 12 participants at 12 months compared to baseline. Participants were divided equally into a low-dose group (3.15 million cells) and a high-dose group (6.30 million cells).
A9-DPC (TED-A9) consists of high-purity ventral midbrain dopaminergic progenitor cells derived from human embryonic stem cells (hESCs) under rigorous GMP conditions.
A total of 12 participants received bilateral putamen transplantation with either a low-dose (3.15 million cells; n = 6) or a high-dose (6.30 million cells; n = 6) of A9-DPC, with ...
